Macro Finance
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
CNBC Business·August 6, 2026·1 min read
Eli Lilly is widening its lead over Novo Nordisk in the obesity drug market after their latest earnings reports. Novo Nordisk is racing to regain market share and restore investor confidence in its pipeline. The competitive divide between the two pharmaceutical companies is growing as Lilly pulls ahead.
Read at CNBC BusinessDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.